Kyverna Publications
Comprehensive Immune Profiling of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy in Patients with Autoimmune Disease
Chou J, et al.
Annual American College of Rheumatology Convergence, Oral, Abstract 0778
Preclinical Development and Manufacturability of KYV-201, an Investigational Allogeneic Anti-CD19 Chimeric Antigen Receptor T Cell for the Treatment of Autoimmune Disease
Mahne A, et al.
American College of Rheumatology Annual Convergence, Poster, Abstract #0008
Preclinical Manufacturability and Activity of KYV-102 from Patients with Systemic Lupus Erythematosus Using Ingenui-T: A Rapid, Autologous Chimeric Antigen Receptor T-Cell Manufacturing Solution Utilizing Whole Blood
Kwong B, et al.
American College of Rheumatology Annual Convergence, Poster, Abstract #0011
Activity and Manufacturing of KYV-101 Anti-CD19 Chimeric Antigen Receptor T Cells Derived from Patients With Neurologic Autoimmune Diseases
Cheng J, et al.
ECTRIMS Congress 2024, Poster #P312
Design of KYSA-6, a Phase 2, Open-Label, Multicenter Study of KYV-101, a Novel Fully Human Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy in Refractory Generalized Myasthenia Gravis
Haghikia A, et al.
ECTRIMS Congress 2024, Poster #P1628
Development of Ingenui-T, a Rapid Autologous Chimeric Antigen Receptor (CAR)-T Manufacturing Solution Using Whole Blood, for Treatment of Autoimmune Disease
Anaya D, et al.
ISCT Annual Meeting 2024, Abstract #4070843
CD19-targeted chimeric antigen receptor T cell therapy in two patients with multiple sclerosis
Fischbach F, et al.
Med. Published online March 29, 2024
First Two US Patients With Lupus Nephritis (LN) Treated With Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy: Preliminary Results From the KYSA-1 Phase 1/2, Multicenter Study of KYV-101
Podoll A, et al.
14th European Lupus Meeting, 2024
Preclinical Activity of KYV-101 Anti-CD19 CAR T Cells Derived From Patients With Multiple Sclerosis
Park S, et al.
ACTRIMS Forum 2024, Poster #P138
Anti-CD19 CAR T cells for refractory myasthenia gravis
Haghikia A, et al.
Lancet Neurology 2023;22:P1104-1105
KYV-101, a Fully Human Anti-CD19 CAR T Cell Therapy, Demonstrates CAR-Mediated and CD19-Dependent Activity Against Autologous B Cells from Patients with Autoimmune Disease
Park S, et al.
ACR Convergence 2023, Abstract #0904
Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma
Brudno JN, et al.
Nat Med 2020;26:270-280
Other Publications of Interest
Preclinical Development of KYV-201, an Investigational Allogeneic Anti-CD19 CAR T Cell for the Treatment of Autoimmune Disease
Mahne A, et al.
EULAR Congress 2024, Poster #POS0462
Serum Proteomic Analysis Identifies Markers Associated With Anti-CD19 CAR T Therapeutic Response in Autoimmune Diseases
Chou J, et al.
EULAR Congress 2024, Poster #POS0464
Serum Proteomic Analysis Identifies Markers Associated With Anti-CD19 CAR T Therapeutic Response in Autoimmune Diseases
Chou J, et al.
ASGCT 27th Annual Meeting 2024, Abstract #1820
Preclinical Development of KYV-201, an Investigational Allogeneic Anti-CD19 CAR T Cell for the Treatment of Autoimmune Disease
Mahne A, et al.
ASGCT 27th Annual Meeting 2024, Abstract #1810
CD19-Targeting CAR T Cells for Myositis and Interstitial Lung Disease Associated With Antisynthetase Syndrome
Pecher AC, et al.
JAMA 2023;329(24):2154-2162
Treatment of a patient with severe systemic sclerosis (SSc) using CD19-targeted CAR T cells
Bergmann C, et al.
Ann Rheum Dis 2023; 82(8):1117-1120
CD19-targeted CAR T cells in refractory antisynthetase syndrome
Müller F, et al.
Lancet 2023;401(10379):815-818
Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus
Mackensen A, et al.
Nat Med 2022;28:2424-2132
CD19-Targeted CAR T Cells in Refractory Systemic Lupus Erythematosus
Mougiakakos D, et al.
N Engl J Med 2021;385:567-569
Function of Novel Anti-CD19 Chimeric Antigen Receptors with Human Variable Regions Is Affected by Hinge and Transmembrane Domains
Alabanza L, et al.
Mol Ther 2017 Nov 1;25(11):2452-2465